Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
Status:
RECRUITING
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are:
* What medical problems do participants have when taking GT-02287?
* How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)?
* Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease?
Participants will:
* visit the clinic to assess if they qualify for the study (30-day Screening Period)
* if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period)
* visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period.
* visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).